…
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by life science, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Waters Corporation makes analytical instruments, software and consumables centered on liquid chromatography and mass spectrometry for pharmaceutical, biotech, food safety and environmental labs. Long-term growth may be supported by expanding biopharma R&D, recurring consumables and services from its installed base and regulatory trends that could increase demand for advanced analytics.
Major risks include cyclical capital-equipment spending, strong competition from larger instrument makers and exposure to pharmaceutical R&D budgets plus execution and supply-chain disruption risks that could dent sales and margins.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 837.85M | 806.19M | 610.91M | 678.24M | 682.15M |
| Net income | 707.75M | 692.84M | 521.57M | 592.20M | 593.79M |
| Selling general administrative | 658.03M | 626.97M | 553.70M | 534.79M | 536.90M |
| Selling and marketing expenses | - | - | 553.70M | - | - |
| Gross profit | 1723.77M | 1629.34M | 1358.68M | 1395.90M | 1427.37M |
| Reconciled depreciation | 130.42M | 131.68M | 125.36M | 105.30M | 108.41M |
| Ebit | 873.39M | 821.71M | 645.49M | 708.46M | 691.55M |
| Ebitda | 1015.84M | 975.75M | 787.19M | 810.17M | 799.96M |
| Depreciation and amortization | 142.45M | 154.05M | 141.70M | 101.71M | 108.41M |
| Non operating income net other | - | 29.42M | 14.49M | 18.47M | -8.99M |
| Operating income | 873.39M | 821.71M | 645.49M | 708.46M | 739.77M |
| Other operating expenses | 2088.76M | 1959.00M | 1711.75M | 1698.14M | 1680.58M |
| Interest expense | 37.78M | 32.72M | 32.80M | 26.63M | 9.83M |
| Tax provision | 130.09M | 113.35M | 89.34M | 86.04M | 88.35M |
| Interest income | 37.78M | 32.72M | 32.80M | 22.06M | 38.81M |
| Net interest income | -37.78M | -32.72M | -32.80M | -26.63M | -9.83M |
| Extraordinary items | - | - | 0.00M | 3.23M | -1.44M |
| Non recurring | - | 5.17M | 8.12M | - | -0.43M |
| Income tax expense | 130.09M | 113.35M | 89.34M | 86.04M | 88.35M |
| Total revenue | 2971.96M | 2785.87M | 2365.36M | 2406.60M | 2419.93M |
| Total operating expenses | 840.58M | 802.47M | 705.06M | 687.44M | 688.02M |
| Cost of revenue | 1248.18M | 1156.53M | 1006.69M | 1010.70M | 992.56M |
| Total other income expense net | -35.55M | -15.51M | -34.58M | -30.22M | -47.37M |
| Net income from continuing ops | 707.75M | 692.84M | 521.57M | 592.20M | 593.79M |
| Net income applicable to common shares | 707.75M | 692.84M | 521.57M | 592.20M | 593.79M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 3281.45M | 3094.93M | 2839.92M | 2557.05M | 3727.43M |
| Intangible assets | 227.40M | 242.40M | 258.64M | 240.20M | 246.90M |
| Other current assets | 103.91M | 90.91M | 80.29M | 67.06M | 68.05M |
| Total liab | 2776.97M | 2727.38M | 2607.78M | 2773.34M | 2160.17M |
| Total stockholder equity | 504.49M | 367.55M | 232.14M | -216.28M | 1567.26M |
| Other current liab | 388.10M | 328.24M | 356.77M | -225.36M | -233.13M |
| Common stock | 1.62M | 1.62M | 1.62M | 1.61M | 1.60M |
| Capital stock | 1.62M | 1.62M | 1.62M | 1.61M | 1.60M |
| Retained earnings | 8508.59M | 7800.83M | 7107.99M | 6587.40M | 5995.20M |
| Other liab | 399.46M | 1213.51M | 1251.26M | 534.32M | 563.07M |
| Good will | 430.33M | 437.87M | 444.36M | 356.13M | 355.61M |
| Other assets | 381.52M | 328.73M | 241.88M | 133.05M | 117.57M |
| Cash | 480.53M | 501.23M | 436.69M | 335.71M | 796.28M |
| Cash and equivalents | 481.39M | 497.22M | 430.24M | 335.50M | 601.90M |
| Total current liabilities | 785.74M | 680.51M | 804.98M | 1681.16M | 1148.35M |
| Current deferred revenue | 227.91M | 227.56M | 198.24M | 176.36M | 164.97M |
| Net debt | 1170.78M | 1012.64M | 919.82M | 1345.45M | 1500.24M |
| Short term debt | 76.43M | 27.91M | 177.76M | 1681.16M | 1148.35M |
| Short long term debt | 50.00M | - | 150.00M | 100.37M | 0.18M |
| Short long term debt total | 1651.31M | 1513.87M | 1356.52M | 1681.16M | 2296.52M |
| Other stockholder equity | -7864.15M | -7323.03M | -6759.52M | -6685.82M | -4311.58M |
| Property plant equipment | 582.22M | 547.91M | 494.00M | 417.34M | 343.08M |
| Total current assets | 1659.99M | 1538.03M | 1320.74M | 1245.43M | 2595.11M |
| Long term investments | - | - | - | 4.49M | 1.09M |
| Net tangible assets | -153.24M | -312.71M | 232.14M | -216.28M | 964.74M |
| Short term investments | 0.86M | 68.05M | 6.45M | 1.43M | 938.94M |
| Net receivables | 722.89M | 612.65M | 573.32M | 587.73M | 568.32M |
| Long term debt | 1574.88M | 1513.87M | 1356.52M | 1580.80M | 1148.17M |
| Inventory | 455.71M | 356.10M | 304.28M | 320.55M | 291.57M |
| Accounts payable | 93.30M | 96.80M | 72.21M | 49.00M | 68.17M |
| Accumulated other comprehensive income | -141.57M | -111.86M | -117.94M | -119.47M | -117.97M |
| Common stock total equity | - | 1.62M | 1.62M | 1.61M | 1.60M |
| Retained earnings total equity | - | 7800.83M | 7107.99M | 6587.40M | 5995.20M |
| Treasury stock | - | -9437.91M | -8788.98M | -8612.58M | -6146.32M |
| Non currrent assets other | 381.52M | 328.73M | 322.17M | 297.95M | 186.72M |
| Non current assets total | 1621.46M | 1556.90M | 1519.18M | 1311.63M | 1132.32M |
| Capital lease obligations | 88.54M | 87.53M | 95.96M | 94.01M | - |
| Long term debt total | 1574.88M | 1513.87M | 1206.52M | 1580.80M | 1148.17M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -107.97M | -63.36M | -5.02M | 941.47M | 1810.87M |
| Change to liabilities | 73.85M | -5.96M | 99.87M | -30.13M | -54.65M |
| Total cashflows from investing activities | -107.97M | -231.63M | -264.09M | 768.80M | 1683.30M |
| Net borrowings | 60.00M | 151.46M | -325.37M | 532.26M | -850.16M |
| Total cash from financing activities | -509.63M | -438.27M | -440.50M | -1872.68M | -2119.52M |
| Change to operating activities | -81.17M | -107.17M | 96.72M | -67.30M | 20.62M |
| Net income | 707.75M | 692.84M | 521.57M | 592.20M | 593.79M |
| Change in cash | -20.70M | 64.54M | 100.98M | -460.56M | 153.96M |
| Begin period cash flow | 501.23M | 436.69M | 335.71M | 796.28M | 642.32M |
| End period cash flow | 480.53M | 501.23M | 436.69M | 335.71M | 796.28M |
| Total cash from operating activities | 611.66M | 747.27M | 790.51M | 643.09M | 604.45M |
| Depreciation | 130.42M | 131.68M | 135.35M | 105.30M | 108.41M |
| Other cashflows from investing activities | 75.49M | -63.36M | -86.69M | -8.84M | -31.49M |
| Change to inventory | -101.90M | -67.25M | 18.94M | -31.85M | -25.40M |
| Change to account receivables | -137.87M | -62.45M | 37.47M | -22.20M | -47.92M |
| Sale purchase of stock | -626.06M | -648.93M | -196.41M | -2469.26M | -1315.11M |
| Other cashflows from financing activities | 261.43M | 560.65M | 396.27M | 987.06M | 46.02M |
| Change to netincome | 20.58M | 29.92M | 41.12M | 48.20M | 39.95M |
| Capital expenditures | 183.46M | 168.27M | 172.38M | 163.82M | 127.56M |
| Change receivables | - | -62.45M | 37.47M | -22.20M | -47.92M |
| Cash flows other operating | - | 21.57M | -53.82M | -18.43M | -9.74M |
| Cash and cash equivalents changes | - | 77.37M | 85.91M | -460.79M | 168.23M |
| Change in working capital | -269.08M | -107.17M | 96.72M | -92.98M | -135.30M |
| Stock based compensation | 42.56M | 29.92M | 36.87M | 38.58M | 37.54M |
| Other non cash items | 31.99M | -16.63M | 2.69M | -9.62M | -2.40M |
| Free cash flow | 428.20M | 579.01M | 618.12M | 479.26M | 476.88M |
Sector: Healthcare Industry: Diagnostics & Research
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| WAT Waters Corporation |
4.52 1.00% |
457.60 | 30.04 | 25.97 | 6.38 | 21.11 | 7.13 | 21.25 |
| TMO Thermo Fisher Scientific Inc |
17.82 2.63% |
694.76 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
3.91 1.73% |
230.25 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| WUXIF WuXi AppTec Co. Ltd |
- -% |
25.45 | 22.29 | 17.95 | 1.53 | 5.98 | 8.39 | 14.30 |
| WUXAY WuXi AppTec Co. Ltd |
-0.31 1.23% |
24.85 | 23.28 | 18.73 | 1.51 | 6.24 | 8.39 | 14.30 |
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by life science, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Dr. Udit Batra Ph.D. | Pres, CEO & Director | 1971 |
| Mr. Amol Chaubal | Sr. VP & CFO | 1977 |
| Dr. Belinda Gaye Hyde Ph.D. | Sr. VP & Chief HR Officer | 1971 |
| Mr. Jonathan M. Pratt | Sr. VP of Waters Division | 1970 |
| Ms. Jianqing Y. Bennett | Sr. VP of TA Instruments Division | 1970 |
| Mr. Christos Ross | Sr. VP of Global Operations | NA |
| Caspar Tudor | Manage of Investor Relation | NA |
| Ms. Keeley A. Aleman | Sr. VP, Gen. Counsel & Corp. Sec. | 1977 |
| Kevin Kempskie | Sr. Director of PR | NA |
| Ms. Kristen Garvey | VP of Corp. Communications | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.